AEGiS-PRn: Simplex Medical Systems, Inc. Receives Notification From Spain and Initial Order from Costa Rica

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Simplex Medical Systems, Inc. Receives Notification From Spain and Initial Order from Costa Rica

PR Newswire; Monday December 8, 12:04 pm EST

HALLANDALE, Fla., Dec. 8 /PRNewswire/ -- Simplex Medical Systems, Inc. (OTC Bulletin Board: SMLX - news) announced today that they have received notification from Spain's Ministry of Health, which allows for the importation of the Simplex Rapid HIV Saliva Test(TM), Simplex Rapid Saliva Test(TM) for Hepatitis, Simplex P.S.A. Blood Test, which tests a patient for the existence of prostate cancer, Simplex Rapid Saliva Test(TM) for H.pylori which indicates the existence of stomach ulcers, as well as the Simplex Rapid Saliva Test(TM) for drugs that determines the existence of cocaine and opiates in a patient's system.

After due consideration and examination of the Simplex Products, Spain's Ministry of Health has determined that these products are not subject to regulation by the Spanish Ministry of Health, and can be imported and distributed throughout Spain, subject to their country's commercial law and consumer protection law.

Additionally Simplex announced they have received their first order for The Simplex Rapid HIV Saliva Test(TM) from Costa Rica. The first shipment is ready to be sent January of 1998.

"With each foreign approval and order, our Company takes a major step toward accomplishing our mission to become a premier medical diagnostic company with a global presence," stated Henry Schur of Simplex.

The Simplex Rapid Saliva Tests(TM), are point of use diagnostic tests that screen a patient's saliva within minutes to determine the presence of certain antibodies. The Simplex Rapid Saliva Test(TM), is a cost-effective way to screen for a number of antibodies, and requires little training to administer.

Simplex has received approval from: Brazil, Venezuela, Italy, Hong Kong, Spain and France for various products, as well as 510K approval in the United States for the Simplex Jet Stream Airbrator, which Sybron Dental Specialties (NYSE: SYB - news) has recently signed a contract to distribute worldwide.

Simplex Medical Systems, Inc. is engaged in the development, manufacture, acquisition and marketing of a variety of products in the medical and dental industry. All Simplex Medical Systems' products are manufactured in the United States in FDA registered facilities. Some of the Company's products are currently being evaluated in the United States, Russia, Paraguay, Mexico, Venezuela, India, Thailand, Philippines, France, and Mainland China.

Any forward-looking statements contained in this press release are based upon assumptions believed by the Company to be reasonable and attainable, but they are subject to important factors relating to the Company's operations and business environment, as detailed in the Company's Securities and Exchange Commission filings, which may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward-looking statements.

SOURCE: Simplex Medical Systems, Inc.

Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
971208
PR971207

Copyright © 1997 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .